{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:31:24Z","timestamp":1746556284132},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40261-019-00774-9","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T10:03:06Z","timestamp":1552903386000},"page":"533-542","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prediction Model for Significant Bleeding in Patients with Supratherapeutic International Normalized Ratio After Oral Administration of Warfarin"],"prefix":"10.1007","volume":"39","author":[{"given":"Leili","family":"Pourafkari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidin","family":"Baghbani-Oskouei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Savadi-Oskouei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samad","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raziye","family":"Parizad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezou","family":"Tajlil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader D.","family":"Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"issue":"13","key":"774_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969\u201374.","journal-title":"N Engl J Med"},{"issue":"9397","key":"774_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","volume":"362","author":"Investigators ESCoBotSI","year":"2003","unstructured":"Investigators ESCoBotSI. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691\u20138.","journal-title":"Lancet"},{"issue":"15","key":"774_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425\u201334.","journal-title":"N Engl J Med"},{"issue":"9","key":"774_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","volume":"289","author":"JH Gurwitz","year":"2003","unstructured":"Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107\u201316.","journal-title":"JAMA"},{"issue":"9","key":"774_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/0003-4819-133-9-200011070-00010","volume":"133","author":"RJ Beyth","year":"2000","unstructured":"Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med. 2000;133(9):687\u201395.","journal-title":"Ann Intern Med"},{"issue":"5","key":"774_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/europace\/eur126","volume":"13","author":"GY Lip","year":"2011","unstructured":"Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13(5):723\u201346.","journal-title":"Europace"},{"issue":"22","key":"774_CR7","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864\u201370.","journal-title":"JAMA"},{"issue":"2","key":"774_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"4","key":"774_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","volume":"58","author":"MC Fang","year":"2011","unstructured":"Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395\u2013401.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"774_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1378\/chest.12-0608","volume":"143","author":"V Rold\u00e1n","year":"2013","unstructured":"Rold\u00e1n V, Mar\u00edn F, Fern\u00e1ndez H, Manzano-Fernandez S, Gallego P, Vald\u00e9s M, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a \u201creal-world\u201d population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143(1):179\u201384.","journal-title":"Chest"},{"issue":"3","key":"774_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10840-014-9930-y","volume":"40","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014;40(3):277\u201384.","journal-title":"J Interv Card Electrophysiol"},{"issue":"11","key":"774_CR12","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.amjmed.2012.04.005","volume":"125","author":"J Donz\u00e9","year":"2012","unstructured":"Donz\u00e9 J, Rodondi N, Waeber G, Monney P, Cornuz J, Aujesky D. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med. 2012;125(11):1095\u2013102.","journal-title":"Am J Med"},{"issue":"9","key":"774_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"S Apostolakis","year":"2012","unstructured":"Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol. 2012;60(9):861\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"774_CR14","doi-asserted-by":"publisher","first-page":"606\u201312.e1","DOI":"10.1016\/j.ahj.2011.07.001","volume":"162","author":"JP Piccini","year":"2011","unstructured":"Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011;162(4):606\u201312.e1.","journal-title":"Am Heart J"},{"issue":"10035","key":"774_CR15","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","volume":"387","author":"Z Hijazi","year":"2016","unstructured":"Hijazi Z, Oldgren J, Lindb\u00e4ck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302\u201311.","journal-title":"Lancet"},{"key":"774_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijcard.2016.04.167","volume":"217","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2016","unstructured":"Garc\u00eda-Fern\u00e1ndez A, Mar\u00edn F, Rold\u00e1n V, Galcer\u00e1-Jornet E, Mart\u00ednez-Mart\u00ednez JG, Vald\u00e9s M, et al. The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. Int J Cardiol. 2016;217:42\u20138.","journal-title":"Int J Cardiol"},{"issue":"01","key":"774_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1160\/TH11-12-0827","volume":"107","author":"H Omran","year":"2012","unstructured":"Omran H, Bauersachs R, R\u00fcbenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Thromb Haemost. 2012;107(01):65\u201373.","journal-title":"Thromb Haemost"},{"issue":"9","key":"774_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22435","volume":"38","author":"W Zhu","year":"2015","unstructured":"Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38(9):555\u201361.","journal-title":"Clin Cardiol"},{"issue":"46","key":"774_CR19","first-page":"3258","volume":"36","author":"EC Obrien","year":"2015","unstructured":"Obrien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258\u201364.","journal-title":"Eur Heart J"},{"issue":"12","key":"774_CR20","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500\u201310.","journal-title":"Eur Heart J"},{"issue":"6","key":"774_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","volume":"129","author":"K Senoo","year":"2016","unstructured":"Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med. 2016;129(6):600\u20137.","journal-title":"Am J Med"},{"issue":"9","key":"774_CR22","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.amjcard.2017.07.051","volume":"120","author":"X Yao","year":"2017","unstructured":"Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol. 2017;120(9):1549\u201356. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.051\n                    \n                  .","journal-title":"Am J Cardiol"},{"issue":"2","key":"774_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","volume":"105","author":"RJ Beyth","year":"1998","unstructured":"Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91\u20139.","journal-title":"Am J Med"},{"issue":"10","key":"774_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/qjmed\/hcm076","volume":"100","author":"M Hughes","year":"2007","unstructured":"Hughes M, Lip G. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599\u2013607.","journal-title":"QJM"},{"issue":"2","key":"774_CR25","first-page":"268","volume":"101","author":"G Palareti","year":"2009","unstructured":"Palareti G, Cosmi B. Bleeding with anticoagulation therapy: who is at risk, and how best to identify such patients. Thromb Haemost. 2009;101(2):268\u201378.","journal-title":"Thromb Haemost"},{"issue":"2","key":"774_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"774_CR27","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484\u20138.","journal-title":"Blood"},{"issue":"21","key":"774_CR28","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.114.011204","volume":"130","author":"L Wallentin","year":"2014","unstructured":"Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130(21):1847\u201358.","journal-title":"Circulation"},{"issue":"5","key":"774_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10620-008-0446-0","volume":"54","author":"K Bayan","year":"2009","unstructured":"Bayan K, T\u00fcz\u00fcn Y, Y\u0131lmaz \u015e, Dursun M, Canoruc F. Clarifying the relationship between ABO\/Rhesus blood group antigens and upper gastrointestinal bleeding. Dig Dis Sci. 2009;54(5):1029\u201334.","journal-title":"Dig Dis Sci"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00774-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:13:15Z","timestamp":1584403995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00774-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00774-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"18 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Leili Pourafkari, Aidin Baghbani-Oskouei, Safa Savadi-Oskouei, Samad Ghaffari, Raziye Parizad, Arezou Tajlil, and Nader D. Nader have no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Declaration of Helsinki and the study protocol was reviewed and approved by the Institutional Review Board and Ethics Committee of Tabriz University of Medical Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was exempted from the informed consent process because of the retrospective design of the study, but all patient data were handled with special care to assure that patient confidentiality was maintained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}